Results 21 to 30 of about 2,785,604 (176)

Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up

open access: yesIndian Journal of Ophthalmology, 2015
Aims: The aim was to evaluate circulating levels of reactive oxygen species (ROS) and changes in central macular thickness (CMT) in patients with nonproliferative diabetic retinopathy (NPDR) after antioxidant supplementation.
Daniela Domanico   +5 more
doaj   +1 more source

Loop myopexy with true muscle transplantation for very large angle heavy eye syndrome patient

open access: yesIndian Journal of Ophthalmology, 2015
A 42-year-old man presenting with complaints of squint for last 20 years. His visual acuity was 20/400 in right eye (RE) and 20/30 in left eye (LE) with glasses. His refraction was RE -16.75/-2.5 D cycl 180 and LE was -14.5/-1.5 D cycl 180.
Jitendra Jethani, Sonal Amin
doaj   +1 more source

Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy

open access: yesIndian Journal of Ophthalmology, 2015
Purpose: The purpose was to measure the concentrations of various cytokines and growth factors (including vascular endothelial growth factor [VEGF] and pigment epithelium-derived factor [PEDF]) in the vitreous of patients with proliferative diabetic ...
V V Chernykh   +4 more
doaj   +1 more source

Ocular pressure waveform reflects ventricular bigeminy and aortic insufficiency

open access: yesIndian Journal of Ophthalmology, 2015
Ocular pulse amplitude (OPA) is defined as the difference between maximum and minimum intraocular pressure (IOP) during a cardiac cycle. Average values of OPA range from 1 to 4 mmHg.
Jean B Kassem   +5 more
doaj   +1 more source

Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab

open access: yesIndian Journal of Ophthalmology, 2015
Aims: To evaluate the 1-month efficacy of intravitreal triamcinolone acetonide (TA) in treating macular edema secondary to retinal vein occlusion (RVO) that was refractory to intravitreal bevacizumab.
Seul Gi Yoo   +4 more
doaj   +1 more source

Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT

open access: yesHealth Technology Assessment, 2021
Background: Patients diagnosed with advanced primary open-angle glaucoma are at a high risk of lifetime blindness. Uncertainty exists about whether primary medical management (glaucoma eye drops) or primary surgical treatment (augmented trabeculectomy ...
Anthony J King   +14 more
doaj   +1 more source

Glare factor plotted against Glaucoma Probability Score (GPS).

open access: yes, 2015
The glare factor, which is the difference between log contrast sensitivity with glare and without glare, plotted against the Glaucoma Probability Score (GPS): an automated optic disc analysis system that shows the extent of damage to optic disc contour ...
Jan Lauritzen (751275)   +5 more
core   +1 more source

Marginal effects of glaucoma knowledge.

open access: yes, 2021
a. Shows the average marginal effect of glaucoma knowledge score by education at various age intervals. b. Shows the average marginal effect of glaucoma knowledge score by sex at various age intervals. c.
Jiahn-Shing Lee (726148)   +5 more
core   +1 more source

Fundus imaging with a nasal endoscope

open access: yesIndian Journal of Ophthalmology, 2015
Wide field fundus imaging is needed to diagnose, treat, and follow-up patients with retinal pathology. This is more applicable for pediatric patients as repeated evaluation is a challenge.
P Mahesh Shanmugam   +2 more
doaj   +1 more source

Reproducibility of the Heidelberg retina tomograph III glaucoma probability score

open access: yes, 2009
PURPOSE: To evaluate the intrasession reproducibility of the Heidelberg Retina Tomograph III (HRT III) Glaucoma Probability Score (GPS) and analyze the factors that may affect it.
G. Taibbi   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy